Early detection of colonic polyps and their prompt removal is a fundamental goal of colorectal cancer screening and prevention. Results of a new multicentre study demonstrate sensitivity for the ScheBo M2-PK Quick test of 92.8% for bowel cancer and 69.4% for polyps. The ScheBo M2-PK Quick test detected twice as many bowel cancer cases and nearly six times the number of polyps compared with an immunological faecal occult blood test (FIT) also included in the study.
Epredia was established in July 2019 through the acquisition by PHC Group of the Anatomical Pathology division of Thermo Fisher Scientific. Our name has changed, however as a standalone business our mission remains the same: to improve lives by enhancing cancer diagnostics.
We are powered by the quality brands you know and trust, such as...
The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE
20 - 21 January, 2026
Grand Hotel, Birmingham
10 - 11 February, 2026
10 Union Street, London, SE1 1SZ
2 March, 2026
Henry B. González Convention Center, San Antonio, Texas, USA
21 - 26 March, 2026
ICC Belfast, Northern Ireland
13 - 16 April, 2026
